170 results on '"Thijs, Judith L"'
Search Results
2. Unraveling heterogeneity in pediatric atopic dermatitis: Identification of serum biomarker based patient clusters
3. Early and Long-Term Effects of Dupilumab Treatment on Circulating T-Cell Functions in Patients with Moderate-to-Severe Atopic Dermatitis
4. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry
5. Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers
6. Moving toward endotypes in atopic dermatitis: Identification of patient clusters based on serum biomarker analysis
7. Current and Future Biomarkers in Atopic Dermatitis
8. Dupilumab after the 2017 approval for the treatment of atopic dermatitis: whatʼs new and whatʼs next?
9. Combinatorial Screening Identifies Novel Promiscuous Matrix Metalloproteinase Activities that Lead to Inhibition of the Therapeutic Target IL-13
10. EASI p-EASI: Utilizing a combination of serum biomarkers offers an objective measurement tool for disease severity in atopic dermatitis patients
11. Multiplex platform technology and bioinformatics are essential for development of biomarkers in atopic dermatitis
12. Ocular surface disease is common in moderate-to-severe atopic dermatitis patients
13. ZFP36 family members regulate the pro-inflammatory features of psoriatic dermal fibroblasts
14. Unraveling heterogeneity in pediatric atopic dermatitis: identification of serum biomarker based patient clusters
15. Ocular surface disease is common in moderate‐to‐severe atopic dermatitis patients
16. Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry
17. Conjunctival inflammation in dupilumab‐treated atopic dermatitis comprises a multicellular infiltrate with elevated T1/T17 cytokines: A case series study
18. Early and Long-Term Effects of Dupilumab Treatment on Circulating T-Cell Functions in Patients with Moderate-to-Severe Atopic Dermatitis
19. Conjunctival inflammation in dupilumab-treated atopic dermatitis comprises a multicellular infiltrate with elevated T1/T17 cytokines: A case series study
20. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry
21. Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers
22. EASI p‐EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers
23. Two‐year drug survival of dupilumab in a large cohort of difficult‐to‐treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry
24. Early identification of atopic dermatitis patients in need of systemic immunosuppressive treatment
25. Een baby met uitgebreide blaren aan handen en voeten
26. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry
27. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry
28. EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers
29. Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry
30. Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis.
31. Serum biomarker profiles suggest that atopic dermatitis is a systemic disease
32. Endotypes in constitutioneel eczeem
33. Dupilumab is very effective in a large cohort of difficult‐to‐treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry
34. Biomarkers detected in dried blood spots from atopic dermatitis patients strongly correlate with disease severity
35. Biomarkers detected in dried blood spots from atopic dermatitis patients strongly correlate with disease severity
36. EASI p-EASI : Predicting disease severity in atopic dermatitis patients treated with cyclosporin A
37. Early identification of atopic dermatitis patients in need of systemic immunosuppressive treatment
38. Biomarkers detected in dried blood spots from atopic dermatitis patients strongly correlate with disease severity
39. Een baby met uitgebreide blaren aan handen en voeten
40. EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with cyclosporin A
41. Towards personalized treatment in atopic dermatitis
42. EASI p‐ EASI : Predicting disease severity in atopic dermatitis patients treated with cyclosporin A
43. Dupilumab in atopic dermatitis: rationale, latest evidence and place in therapy
44. Dupilumab in atopic dermatitis : rationale, latest evidence and place in therapy
45. Dupilumab in atopic dermatitis: rationale, latest evidence and place in therapy
46. Serum biomarker profiles suggest that atopic dermatitis is a systemic disease
47. Endotypes in constitutioneel eczeem
48. EASI p-EASI: Utilizing a combination of serum biomarkers offers an objective measurement tool for disease severity in atopic dermatitis patients
49. Multiplex platform technology and bioinformatics are essential for development of biomarkers in atopic dermatitis
50. Moving toward endotypes in atopic dermatitis: Identification of patient clusters based on serum biomarker analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.